🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

INVO Fertility, Inc. IVF PHARMA

Healthcare · Medical Devices · United States
https://www.invofertility.com
Company Profile ↓
$0.98
-98.57% 1Y
Mkt Cap$2.46M
P/B0.14
52W High$70.00
52W Low$0.91
Book Value$7.01
EPS (TTM)$357.88

Company Overview

INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services and INVOcell Device segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 38.5% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.24.

Recent Developments

  • Dec 2025 Revenue of $6.84M (+4.3% YoY); net profit $-23.32M.
  • Trailing 12 Months Year-on-year growth — revenue +16.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 38.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:38.51%
1 Year:16.70%

Stock Price Performance

1 Year:-98.57%
6 Months:-76.89%
3 Months:-24.45%
1 Month:-7.34%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$0.91 $70.00
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)43.35 · Neutral
Price Performance
1M-7.34%
3M-24.45%
6M-76.89%
1Y-98.57%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 38.5% over 5 years.

CONS

  • Trading 98.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
0.00
Industry PE
24.83
Forward P/E
-0.12
PEG Ratio
-
Book Value
$7.01
Price to Book
0.14
P/S
0.32
EV/EBITDA
-0.54
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
38.51%
Profit 5Y
-
Revenue (YoY)
16.70%
Earnings (YoY)
-

Profitability & Returns

ROCE
-73.19%
ROE
-55.28%
ROA
-16.41%
Profit Margin
-70.18%
Op Margin
-59.28%
Gross Margin
35.28%
EPS (Latest Qtr)
$-3.38
EPS (TTM)
$357.88

Balance Sheet & Liquidity

Debt/Equity
0.24
Quick Ratio
0.61
Current Ratio
0.71
Debt
$3.92M
Total Assets
$24.66M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.90%
Chg in Prom Hold
-0.08%
FII / Inst Holding
16.89%
Chg in FII Hold
2.66%

Financial Snapshot

Enterprise Value
$2.46M
Total Revenue (TTM)
$7.53M
EBITDA
$-5.37M
Free Cash Flow
$-4.82M
Operating Cash Flow
$-4.77M
Shares Outstanding
2.51M
Gross Margin
35.28%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IVF INVO Fertility, Inc. PHARMA 0.98 0.00 $2.46M 0.00% -73.19% -55.28% 38.51% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ---------------------258.57K246.07K336.07K684.52K208.47K218.87K162.60K146.13K235.32K348.02K315.90K974.89K1.58M1.84M1.43M1.64M---
Gross Profit 5.83K1.95K-7777.05K4132.85K1.42K6.02K-1.90K14.94K3.06K11.38K38.40K66.14K55.39K89.72K93.50K109.67K178.45K603.36K258.64K228.58K224.90K308.67K621.78K193.88K198.46K97.64K67.88K126.20K275.47K---------
Operating Income -191.42K-149.91K-124.35K-104.47K-173.82K-104.67K-131.84K-107.44K-118.76K-180.66K-1.45M-207.37K-166.70K-132.41K-144.30K-140.28K-1.79M-189.88K-349.11K-65.80K-632.36K-1.40M-1.06M-1.27M-1.56M-1.89M-2.27M-2.70M-2.68M-2.53M-2.31M-2.07M-886.29K-1.51M-1.85M-1.30M-1.20M-2.99M-1.64M-1.59M
Net Income -302.68K-104.89K-213.97K-117.32K-186.77K-117.72K-144.66K-4.45M-123.19K-181.31K-1.46M-210.82K-214.87K-136.97K-148.85K-144.72K-1.87M-294.86K-458.57K-241.55K-710.33K-1.44M-1.32M-1.77M-2.45M-1.82M-2.24M-2.77M-2.80M-2.55M-2.55M-2.24M-1.25M-1.60M-2.25M-1.63M-17.40M-3.62M-3.40M-5.54M
Diluted EPS 0.000.000.000.000.000.000.00-0.040.000.00-0.010.000.000.000.000.00-0.010.000.00-0.03-0.15-0.29-0.27-0.36-0.25-0.17-0.24-0.23-4.62-4.19-4.10-3.06-0.70-7.55-22.39-15.11-3,473.93-364.23-39.40-3.38
R&D Expense ------------------00030.05K34.89K112.55K66.27K31.02K55.39K104.18K190.76K175.27K73.52K83.85K2.67K4.88K--265.66K---

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 71.50K56.38K27.06K16.59K11.69K50.90K282.14K494.38K1.48M1.04M4.16M822.20K3.02M6.56M6.84M
Gross Profit 53.59K35.50K16.48K8.91K3.88K35.81K230.19K404.01K1.34M948.53K4.02M490.67K---
Operating Income -703.13K-552.30K-605.23K-1.68M-595.07K-2.11M-640.42K-2.63M-1.79M-5.51M-5.22M-10.63M-6.77M-6.63M-7.24M
Net Income -797.47K-666.45K-760.68K-1.73M-4.96M-2.12M-702.16K-3.08M-2.17M-8.35M-6.65M-10.89M-8.03M-9.26M-23.32M
Diluted EPS -0.01-0.01-0.01-0.02-0.04-0.020.00-0.02-0.45-1.52-0.63-17.97-67.37-3,782.65-214.64
R&D Expense --------0398.43K216.43K544.04K165.94K4.88K-

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Mar 2012Jun 2012Sep 2012Dec 2012Mar 2013Jun 2013Sep 2013Dec 2013Mar 2014Jun 2014Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Total Assets -127.88K128.12K150.27K140.29K125.27K116.61K115.16K114.98K122.54K114.83K105.78K101.57K108.05K113.74K164.81K199.18K579.79K286.23K266.41K777.35K1.80M10.95M10.47M4.10M18.51M46.08M---20.22M
Total Equity -2.48M-2.93M-3.05M-3.13M-3.35M-3.37M-3.60M-3.65M-3.84M-3.81M-3.93M-4.12M-4.24M-4.36M-4.48M-4.04M-4.10M-3.76M-4.62M-4.99M-2.72M-3.71M5.74M7.31M-977.61K892.83K12.58M-27.04M-6.99M5.82M7.22M
Cash & Equivalents 12.53K40388731.46K27.69K7.19K6872.27K7.50K18.03K7.26K8.63K6.27K18.63K24.47K79.62K114.56K492.00K152.40K25.76K212.24K1.24M10.10M5.68M-------
Long Term Debt --------------------------1.13M---744.73K
Total Liabilities -3.05M3.18M3.28M3.49M3.50M3.72M3.77M3.96M3.94M4.05M4.22M4.34M4.47M4.59M4.21M4.30M4.34M4.90M5.26M3.50M5.51M5.20M3.16M5.08M17.61M26.04M-16.19M13.01M13.00M
Current Liabilities -3.05M3.18M3.28M3.49M3.50M3.72M3.77M3.96M3.94M4.05M4.22M4.34M4.47M4.59M4.21M4.30M4.34M4.77M5.13M3.50M1.50M2.29M1.25M3.41M8.00M17.87M-12.14M9.13M10.33M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -117.78K-43.21K-59.92K-19.40K-151.62K-323.90K-181.27K-652.97K1.37M-4.78M-6.03M-6.60M-4.76M-2.97M-7.01M
Investing Cash Flow ----0-15.70K0-19.40K-114.71K-187.25K-2.15M-81.22K-2.49M363.89K-2.75M
Financing Cash Flow 105.66K50.00K70.75K20.00K625.00K054.62K858.86K-229.47K13.82M3.77M1.09M7.39M3.12M11.10M
Capital Expenditure -----0-15.70K-0-19.40K-64.84K-49.26K-415.71K-10.79K-444.72K-183.70K-43.41K
Free Cash Flow -----151.62K-339.60K-181.27K-672.37K1.31M-4.82M-6.45M-6.61M-5.20M-3.16M-7.06M

Ratios (Annual)

Figures in %.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 74.9%63.0%60.9%53.7%33.2%70.3%81.6%81.7%90.6%91.4%96.5%59.7%---
Operating Margin % -983.4%-979.7%-2,236.4%-10,131.3%-5,090.9%-4,146.1%-227.0%-532.8%-120.8%-531.7%-125.4%-1,292.5%-224.0%-101.0%-105.8%
Net Margin % -1,115.3%-1,182.1%-2,810.8%-10,444.1%-42,426.6%-4,173.3%-248.9%-622.2%-146.4%-804.7%-160.0%-1,324.8%-266.0%-141.1%-340.9%
ROE % 27.3%19.8%19.9%39.7%132.0%46.0%14.1%112.9%58.4%-145.3%-91.0%1,114.2%-899.9%-73.6%-322.8%
ROCE % 24.0%16.4%15.9%38.6%15.8%47.0%13.2%96.7%-607.4%-63.7%-56.6%-1,530.6%-64.4%-23.5%-73.2%

Shareholding Pattern

Insiders
0.90%
Institutions
16.89%
Public Float
17.04%

Top Institutional Holders

#Holder% HeldSharesValue
1 Virtu Financial LLC 2.52% 63.17K $61.28K
2 Scientech Research LLC 1.29% 32.34K $31.37K
3 Stonex Group Inc. 0.63% 15.70K $15.23K
4 Susquehanna International Group, LLP 0.46% 11.46K $11.12K
5 Tower Research Capital LLC (TRC) 0.33% 8.15K $7.91K
6 SBI Securities Co., Ltd. - 53 $51
7 Caitong International Asset Management Co., Ltd - 38 $36
8 Danske Bank A/s - 1 $0

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IVF

Yahoo Finance hu, 20 Aug 2026

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

Research from Wisconsin Fertility Institute evaluates ovarian and subendometrial PRP in patients with prior poor IVF response and endometrial-development challengesSARASOTA, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasd…

Yahoo Finance Mon, 17 Aug 2026

INVO Fertility Inc (IVF) (Q2 2026) Earnings Call Highlights: Revenue Surges 17% as Clinic-Level ...

INVO Fertility Inc (IVF) reports strong quarterly growth driven by the Family Beginnings acquisition and improved operational efficiency.

Yahoo Finance Mon, 17 Aug 2026

INVO Fertility Q2 Revenue Rises 17% as Clinic-Level Profitability Improves

INVO Fertility (NASDAQ:IVF) reported a 17% increase in second-quarter 2026 revenue to $2. 18 million as the first full-quarter contribution from Family Beginnings and growth initiatives across its existing clinics expanded the fertility ser…

Yahoo Finance Mon, 17 Aug 2026

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices Clinic platform was profitable on an Adjusted EBITDA basis before corporate operatin…

Yahoo Finance Mon, 22 Jun 2026

INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure

23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet Growth reflects both organic clinic initiatives and acquisition contribution from Family Beginnings, reinforcing INV…

Yahoo Finance ue, 02 Jun 2026

INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q

SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency notice (the "Notice") f…

IVF — Frequently Asked Questions

What is the current share price of INVO Fertility, Inc. (IVF)?

As of 2026-09-19 21:16 PDT, INVO Fertility, Inc. (IVF) trades at $0.98 on NasdaqCM. Its 52-week range is $0.91 to $70.00.

What is the market capitalisation of IVF?

INVO Fertility, Inc. (IVF) has a market capitalisation of $2.46M on NasdaqCM.

What is the return on equity (ROE) of IVF?

IVF has a return on equity (ROE) of -55.28%. Its return on capital employed (ROCE) is -73.19%.

Is IVF a good stock to buy?

This page provides a data-driven analysis of INVO Fertility, Inc. (IVF), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space